Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Daytime Sleepiness Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea

NCT00307944
View directory record Official record
Conditions
Acid Reflux Disease, Obstructive Sleep Apnea
Interventions
Pantoprazole
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)

NCT07540364
View directory record Official record
Conditions
Narcolepsy
Interventions
Samelisant, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Terminated Not applicable Interventional

Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

NCT06395181
View directory record Official record
Conditions
Obstructive Sleep Apnea, Daytime Sleepiness
Interventions
Whole Food Plant-Based Diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829
View directory record Official record
Conditions
Excessive Daytime Sleepiness
Interventions
ORX142 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Lincoln, Nebraska • Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

NCT04072380
View directory record Official record
Conditions
Narcolepsy
Interventions
SUVN-G3031, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

An Open Label Study of FT218 in Subjects With Narcolepsy

NCT04451668
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder, Sleep Disturbance, Sleep Wake Disorders
Interventions
FT218
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Redwood City, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project REST: Club Sports

NCT07103759
View directory record Official record
Conditions
Poor Quality Sleep
Interventions
Refrain from caffeine techniques, Project REST Platform
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Light Exposure to Treat Sleep Disruption in Older People

NCT00427323
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Circadian Rhythm Sleep Disorders, Hypersomnia
Interventions
light exposure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

NCT01124851
View directory record Official record
Conditions
Sleep Disorder
Interventions
ABT-652, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Glendale, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Sep 23, 2026, 5:02 PM EDT
Active, not recruiting Not applicable Interventional

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

NCT02909192
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Light Therapy Device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Sep 23, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

NCT07500090
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
HBS-301 tablet, Placebo
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Peoria, Arizona • Redwood City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

NCT01049984
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
30 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

NCT01485770
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Lemborexant Shift Work Treatment Study

NCT05344443
View directory record Official record
Conditions
Shift-Work Related Sleep Disturbance
Interventions
Lemborexant, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 1 Interventional

Effects of Hemodialysis on the Sleep/Wake Cycle

NCT00460863
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
using cool versus warm dialysate during hemodialysis
Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

NCT04923594
View directory record Official record
Conditions
Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions
mazindol extended release, Placebo
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Start Times and Restful Sleep

NCT04049682
View directory record Official record
Conditions
Excessive Daytime Somnolence, Sleep Deprivation
Interventions
Delayed School Start Time
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 23, 2026, 5:02 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

NCT03433131
View directory record Official record
Conditions
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
71
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 23, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

NCT02720744
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 23, 2026, 5:02 PM EDT